{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:39Z","timestamp":1791953199756,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-026-01503-y","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:23:58Z","timestamp":1791293038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET pharmacokinetics of [\u00b9\u2078F]F-AraG as a marker of T cell activation during immunotherapy with a STING agonist with and without anti-PD-1"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-1804","authenticated-orcid":false,"given":"J. E. E.","family":"Pouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stavenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Wijngaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.","family":"Schuit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P. P.","family":"van Eeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Galette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Bonasera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Menke-van der Houven van Oordt Oord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"10","key":"1503_CR1","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205.","journal-title":"Immunity"},{"key":"1503_CR2","doi-asserted-by":"publisher","unstructured":"AAmouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers. 2021;13(11):2695. https:\/\/doi.org\/10.3390\/cancers13112695.","DOI":"10.3390\/cancers13112695"},{"issue":"7","key":"1503_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405\u201314.","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"1503_CR4","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1158\/0008-5472.CAN-19-0267","volume":"79","author":"J Levi","year":"2019","unstructured":"Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, et al. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Res. 2019;79(13):3455\u201365.","journal-title":"Cancer Res"},{"issue":"12","key":"1503_CR5","first-page":"1869","volume":"65","author":"J Levi","year":"2024","unstructured":"Levi J, Das M, Vasanawala MS, Behl D, Pomper M, Forde PM, et al. [(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. J Nucl Med. 2024;65(12):1869\u201375.","journal-title":"J Nucl Med"},{"issue":"6","key":"1503_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00259-022-06057-4","volume":"50","author":"CWJ van der Weijden","year":"2023","unstructured":"van der Weijden CWJ, Mossel P, Bartels AL, Dierckx R, Luurtsema G, Lammertsma AA, et al. Non-invasive kinetic modelling approaches for quantitative analysis of brain PET studies. Eur J Nucl Med Mol Imaging. 2023;50(6):1636\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1503_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1347267","volume":"11","author":"JJ Eertink","year":"2024","unstructured":"Eertink JJ, Bahce I, Waterton JC, Huisman MC, Boellaard R, Wunder A, et al. The development process of \u201cfit-for-purpose\u201d imaging biomarkers to characterize the tumor microenvironment. Front Med (Lausanne). 2024;11:1347267.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1503_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00259-024-06931-3","volume":"52","author":"JE Wijngaarden","year":"2025","unstructured":"Wijngaarden JE, Slebe M, Pouw JEE, Oprea-Lager DE, Schuit RC, Dickhoff C, et al. Pharmacokinetic analysis and simplified uptake measures for tumour lesion [(18)F]F-AraG PET imaging in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025;52(2):719\u201329.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"1503_CR9","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1088\/0031-9155\/51\/17\/007","volume":"51","author":"M Yaqub","year":"2006","unstructured":"Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET stsudies. Phys Med Biol. 2006;51(17):4217\u201332.","journal-title":"Phys Med Biol"},{"key":"1503_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.aml.2017.05.005","volume":"74","author":"HT Banks","year":"2017","unstructured":"Banks HT, Loyner ML. AIC under the framework of least squares estimation. Appl Math Lett. 2017;74:33\u201345.","journal-title":"Appl Math Lett"},{"issue":"10","key":"1503_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"1503_CR12","doi-asserted-by":"crossref","unstructured":"Omidvari N, Levi J, Abdelhafez YG, Wang Y, Nardo L, Daly ME et al. Total-Body Dynamic Imaging and Kinetic Modeling of [(18)F]F-AraG in Healthy Individuals and a Non-Small Cell Lung Cancer Patient Undergoing Anti-PD-1 Immunotherapy. J Nucl Med. 2024;65(9):1481\u2009\u2013\u20098.13.","DOI":"10.2967\/jnumed.123.267003"},{"key":"1503_CR13","doi-asserted-by":"crossref","unstructured":"Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69\u201394.","DOI":"10.1146\/annurev-immunol-020711-075011"},{"issue":"6220","key":"1503_CR14","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","journal-title":"Science"},{"issue":"9","key":"1503_CR15","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356\u201364.","journal-title":"J Clin Invest"},{"issue":"4","key":"1503_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00262-018-2200-6","volume":"68","author":"V Umansky","year":"2019","unstructured":"Umansky V, Adema GJ, Baran J, Brandau S, Van Ginderachter JA, Hu X, et al. Interactions among myeloid regulatory cells in cancer. Cancer Immunol Immunother. 2019;68(4):645\u201360.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1503_CR17","first-page":"795","volume":"42","author":"OL Munk","year":"2001","unstructured":"Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, Keiding S. Liver Kinetics of Glucose Analogs Measured in Pigs by PET: Importance of Dual-Input Blood Sampling. J Nucl Med. 2001;42(5):795\u2013804.","journal-title":"J Nucl Med"},{"issue":"11","key":"1503_CR18","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1158\/0008-5472.CAN-16-2953","volume":"77","author":"JA Ronald","year":"2017","unstructured":"Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D\u2019Souza A, et al. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res. 2017;77(11):2893\u2013902.","journal-title":"Cancer Res"},{"issue":"9","key":"1503_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/15257770.2015.1047029","volume":"34","author":"A Fyrberg","year":"2015","unstructured":"Fyrberg A, Lotfi K. Nucleoside analog activity in malignant melanoma cell lines. Nucleosides Nucleotides Nucleic Acids. 2015;34(9):639\u201349.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"3","key":"1503_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00109-021-02131-w","volume":"100","author":"K Schott","year":"2022","unstructured":"Schott K, Majer C, Bulashevska A, Childs L, Schmidt MHH, Rajalingam K, et al. SAMHD1 in cancer: curse or cure? J Mol Med (Berl). 2022;100(3):351\u201372.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"1503_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.semnuclmed.2023.08.002","volume":"54","author":"R Slart","year":"2024","unstructured":"Slart R, Martinez-Lucio TS, Boersma HH, Borra RH, Cornelissen B, Dierckx R, et al. [(15)O]H(2)O PET: potential or essential for molecular imaging? Semin Nucl Med. 2024;54(5):761\u201373.","journal-title":"Semin Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01503-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:07:13Z","timestamp":1791950833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01503-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01503-y","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and approved by the institutional review board of the Amsterdam UMC. Informed consent for study participation was obtained from all individual patients included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JEEP became employee and stockholder at GSK during the manuscript revision process. MMM, PG\n                      \u2020\n                      , CAP\n                      \u2020\n                      and TAB\n                      \u2020\n                      are (former\n                      \u2020\n                      ) employees and stockholders of GSK. PG is currently employed by Pfizer and TAB by Perceptive. ADW is editor-in-chief of Nuclear Medicine & Biology. CWMvdHvO received institutional funding from BI, GSK, BMS, AstraZeneca, Pfizer and consulted for GEHealthcare, Eli-Lilly. TDdG holds stocks from LAVA-therapeutics and is scientific advisor for GE Healthcare, LAVA-therapeutics, Mendus, and Vivaldi therapeutics. Cellsight Technologies has reviewed and provided comments on the manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}